Inhibikase Therapeutics Stock Price on November 30, 2024
| IKT Stock | USD 2.92 0.19 6.96% |
If you're considering investing in Inhibikase Stock, it is important to understand the factors that can impact its price. As of today, the current price of Inhibikase Therapeutics stands at 2.92, as last reported on the 30th of November, with the highest price reaching 2.98 and the lowest price hitting 2.76 during the day. Inhibikase Therapeutics is moderately volatile given 3 months investment horizon. Inhibikase Therapeutics holds Efficiency (Sharpe) Ratio of 0.21, which attests that the entity had a 0.21% return per unit of risk over the last 3 months. We were able to collect data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.47% are justified by taking the suggested risk. Use Inhibikase Therapeutics Market Risk Adjusted Performance of 0.8126, risk adjusted performance of 0.1632, and Downside Deviation of 5.71 to evaluate company specific risk that cannot be diversified away.
At this time, Inhibikase Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 3.2 M in 2024. . At this time, Inhibikase Therapeutics' Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 0.65 in 2024, whereas Price Earnings To Growth Ratio is likely to drop 0.02 in 2024. Inhibikase Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Inhibikase |
Sharpe Ratio = 0.2143
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | IKT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.86 actual daily | 61 61% of assets are less volatile |
Expected Return
| 1.47 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Inhibikase Therapeutics is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibikase Therapeutics by adding it to a well-diversified portfolio.
Price Book 26.456 | Enterprise Value Ebitda 0.3409 | Price Sales 2.3 K | Shares Float 1.7 M | Wall Street Target Price 7 |
Related Headline
Seres Therapeutics Headline on 29th of November 2024
Providence Wealth Advisors LLC Grows Stock Position in Seres... by thelincolnianonline.com
Providence Wealth Advisors LLC grew its position in Seres Therapeutics, Inc. by 29.2 percent during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission . The institutional investor owned 98,500 shares of the biotechnology companys stock after acquiring an additional 22,250 shares during
Inhibikase Therapeutics Valuation on November 30, 2024
It is possible to determine the worth of Inhibikase Therapeutics on a given historical date. On November 30, 2024 Inhibikase was worth 2.76 at the beginning of the trading date compared to the closed value of 2.92. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Inhibikase Therapeutics stock. Still, in general, we apply an absolute valuation method to find Inhibikase Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inhibikase Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Inhibikase Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.40 | 2.86 | 2.39 | 2.73 | 293,858 | |
11/29/2024 | 2.76 | 2.98 | 2.76 | 2.92 | 179,157 |
| Backtest Inhibikase Therapeutics | | | Inhibikase Therapeutics History | | | Inhibikase Therapeutics Valuation | Previous |
Inhibikase Therapeutics Trading Date Momentum on November 30, 2024
| On November 29 2024 Inhibikase Therapeutics was traded for 2.92 at the closing time. Highest Inhibikase Therapeutics's price during the trading hours was 2.98 and the lowest price during the day was 2.76 . The net volume was 179.2 K. The overall trading history on the 29th of November did not cause price change. The trading delta at closing time to current price is 5.48% . |
Inhibikase Therapeutics Fundamentals Correlations and Trends
By evaluating Inhibikase Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Inhibikase financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Inhibikase Therapeutics Stock history
Inhibikase Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Inhibikase is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Inhibikase Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Inhibikase Therapeutics stock prices may prove useful in developing a viable investing in Inhibikase Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 5.3 M | 3.2 M | |
| Net Loss | -13.3 M | -12.6 M |
Inhibikase Therapeutics Stock Technical Analysis
Inhibikase Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Inhibikase Therapeutics Period Price Range
Low | November 30, 2024
| High |
0.00 | 0.00 |
Inhibikase Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Inhibikase Therapeutics November 30, 2024 Market Strength
Market strength indicators help investors to evaluate how Inhibikase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inhibikase Therapeutics shares will generate the highest return on investment. By undertsting and applying Inhibikase Therapeutics stock market strength indicators, traders can identify Inhibikase Therapeutics entry and exit signals to maximize returns
Inhibikase Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Inhibikase Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Inhibikase Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Inhibikase to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1632 | |||
| Jensen Alpha | 1.14 | |||
| Total Risk Alpha | 0.2254 | |||
| Sortino Ratio | 0.2142 | |||
| Treynor Ratio | 0.8026 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.